Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp cut its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 21.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,478 shares of the medical equipment provider's stock after selling 7,099 shares during the quarter. Fifth Third Bancorp's holdings in Hologic were worth $1,574,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HOLX. LaFleur & Godfrey LLC increased its position in Hologic by 2.9% during the 4th quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock valued at $9,399,000 after buying an additional 3,655 shares in the last quarter. Empowered Funds LLC boosted its stake in Hologic by 280.3% in the 4th quarter. Empowered Funds LLC now owns 13,704 shares of the medical equipment provider's stock worth $988,000 after purchasing an additional 10,101 shares in the last quarter. Asset Management One Co. Ltd. grew its position in Hologic by 58.9% during the 4th quarter. Asset Management One Co. Ltd. now owns 145,028 shares of the medical equipment provider's stock valued at $10,529,000 after purchasing an additional 53,762 shares during the last quarter. Principal Financial Group Inc. increased its stake in Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock valued at $19,547,000 after purchasing an additional 1,606 shares in the last quarter. Finally, AlphaCentric Advisors LLC purchased a new position in Hologic in the fourth quarter worth about $549,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Royal Bank Of Canada cut their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Argus cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Evercore ISI lowered their price target on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Morgan Stanley decreased their target price on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Twelve equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Hologic currently has a consensus rating of "Hold" and a consensus price target of $77.42.

Hologic Trading Down 1.6%

Shares of Hologic stock traded down $1.04 on Tuesday, reaching $64.14. The company had a trading volume of 3,116,240 shares, compared to its average volume of 2,318,737. The firm's 50-day moving average price is $58.84 and its two-hundred day moving average price is $64.65. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67. The firm has a market cap of $14.29 billion, a price-to-earnings ratio of 15.78, a P/E/G ratio of 2.39 and a beta of 0.55. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The firm's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.03 EPS. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director now owns 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.88% of the stock is owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.